Engineered immune cells take on virus in transplant patients
NCT ID NCT06119256
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether specially engineered immune cells (EBV-TCR-T cells) can safely control Epstein-Barr virus infections in people who have had a stem cell transplant. About 12 participants will receive one to three infusions of donor-derived cells. The main goal is to check for side effects and see if the virus levels drop.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EBV-TCR-T cells (immune cells engineered to target the Epstein-Barr virus)
What this could lead to
If it works, this could point toward a treatment for EBV infections after stem cell transplants, reducing complications.
What could go wrong
This is a very early phase 1 trial with only 12 participants, so it may not show clear benefit or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV INFECTION AFTER ALLOGENIC HSCT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••